|
|
Global Vaccine Congress - First conference
|
VACCINE CONGRESS
Celebrating 25 years of Publication
9 - 11 December 2007 | Amsterdam, The Netherlands |
| Sunday December 9, 2007 |
| 13:30 |
Ray Spier
University of Surrey, UK and
Editor of Vaccine |
Welcome |
Session1
Social issues with vaccines and vaccination
Part one: current issues and areas for development |
| 13:37 |
P.L. Nara
Biological Mimetics Inc, USA |
Perspectives on advancing the field of vaccinology at the wild, domestic, laboratory, veterinary and human interface: not missing the opportunities |
| 14:07 |
L. Hessel
Sanofi Pasteur MSD, France |
25 years of vaccine development: an industry perspective |
| 14:22 |
M.P. Girard
Viovision Lyon, France |
HIV/AIDS vaccines: An update |
| 14:37 |
J. Shiver
Merck Research Laboratories, USA |
Strategies for HIV-1 vaccine development |
| 14:52 |
C. Myint Oo
Chiba Institute of Technology, Japan |
HIV-GagVLPs induce activation of innate and adapted immune responses by activation of dendritic cells, T cells and NK cells |
| 15:07 |
S.T. Turbant
CEA, DSV, iBiTec-S, SPI, LIAS, France |
Evaluation of the immunogenicity of a new Tat candidate vaccine against HIV, in a non human primate model |
| 15:14 |
F. Martinon
CEA, France |
Induction of persistent T Cell responses against HIV in macaques with a multivalent DNA vaccine injected intradermaly with electroporation |
| 15:21 |
K. Alagappan
Long Island Jewish Medical Center, USA |
Protective titers and immunizable diseases among HIV infected patients |
| 15:28 |
D. Weiner
University of Pennsylvania, USA |
Enhanced DNA vaccine potency and immune phenotype targeting HIV-1 |
| 16:00 |
Refreshments, poster session 1 and exhibition viewing |
|
Session 2
Latest status in the development of vaccines for TB, malaria and HIV |
| 16:28 |
X. Bosch
Institut Catala d’oncolgia, Spain |
HPV vaccines for cancer prevention |
| 16:43 |
J.C. Sadoff
Aeras Global TB Vaccine Foundation, USA |
Development of new vaccines to address the TB pandemic |
| 16:58 |
M. Romano
Pasteur Institute Brussel-WIV, Belgium |
Immunogenicity and protective efficacy of ppe44-based tuberculosis subunit vaccines |
| 17:05 |
F. Dobakhti
Zanjan University of Medical Sciences, Iran |
Oral administration of BCG encapsulated in alginate microspheres induces protective immunity in BALB/c mice |
| 17:12 |
A. Dey
All India Institute of Medical Sciences, India |
Developing a chimeric DNA vaccine against tuberculosis and leishmaniasis |
| 17:19 |
G.H. Mitchell
Guy’s Kings College and St. Thomas’ Hospitals’ School of Medicine, UK |
Resisting malaria |
| 17:33 |
A.Reyes-Sandoval
University of Oxford, UK |
Immunogenicity and protective efficacy of simian adenoviral vectors against P. berghei |
| 17:40 |
K. Pusic
University of Hawaii, USA |
Antigenicity and immunogenicity of the P. falciparum merozoite surface protein, MSP1-33 |
| 17:47 |
A.Mohd Nor
University Science Malaysia, Malaysia |
Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacilli Calmette Guerin (BCG expressing the 19kDa C-terminus of merozoite surface protein-1 (MSP-1C) and the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum |
| 17:54 |
V. Chitnis
Pharmexa-Epimmune, USA |
Pre-clinical development of a pre-erythrocytic P. falciparum malaria DNA vaccine based on conserved cytotoxic T Lymphocyte and Helper T Lymphocyte Epitopes delivered by an in vivo electroporation device |
| 18:01 |
M. Roestenberg
Radboud University Nijmegen Medical Centre, Netherlands |
Comparison of safety and immunogenicity of AMA-1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 and AS02A |
| 18:08 |
Discussion |
|
| 18:15 |
G.A. Poland
Mayo Clinic College of Medicine, USA |
Variations in vaccine response: The role of immunogenetics: Bench to bedside to population |
| Reception and poster session 1 |
|
| Monday December 10, 2007 |
Session 3
New and upcoming issues with other vaccines including : Influenza H5N1 vaccines, HPV Vaccines, biowarfare vaccines, respiratory vaccines, diarrhoeal vaccines |
| 8:30 |
A.D.M.E. Osterhaus
Erasmus MC, Netherlands |
Vaccination against emerging viral infections |
| 8:55 |
A.M. Palache
Solvay Pharmaceuticals BV,
Netherlands |
Seasonal influenza control: Urgent time for actions |
| 9:20 |
U. Reichl
Max Planck Institute for Dynamics of complex Technical Systems, Germany |
Influenza vaccines – challenges in optimization of virus yields in mammalian cell culture |
| 9:45 |
M. Rudolf
Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany |
Long-term study under field conditions on the efficacy of commercial, inactivated H5 influenza vaccines against highly pathogenic avian influenza H5 in poultry |
| 9:52 |
S. Mossman
GlaxoSmithKline Biologicals, Belgium |
Immunization of ferrets with low doses of influenza H5N1 antigen formulated with a novel adjuvant system protects against lethal challenge with Heterologous H5N1 Virus |
| 9:59 |
I.Leroux-Roels
Ghent University and Hospital, Belgium |
Pandemic influenza preparation: Cross-reactive immunity with an adjuvanted H5N1 candidate vaccine associated with a good safety profile |
| 10:06 |
C. He
Agricultural University, China |
Whole virion H5N1 inactivated vaccine against highly pathogenic avian influenza |
| 10:13 |
D. Higgins
Dynavax Technologies, USA |
Immunostimulatory DNA conjugated to conserved viral antigens as a universal influenza vaccine |
| 10:28 |
P. Bilsel
Pharmexa-Epimmune, USA |
T-Lymphocyte epitope based vaccine for pandemic influenza |
| 10:35 |
T.V. Nguyen
Company for Vaccine and Biological Production No. 1 (VABIOTECH), Vietnam |
Development of a human H5N1 influenza vaccine by reverse genetics in Vietnam |
| 10:42 |
Discussion |
Cross protective influenza vaccines - prospects |
| 10:55 |
Refreshments, poster session 1 and exhibition viewing |
|
Session 4
Methods of vaccine production focusing on the new areas of plasmid vaccines, whole cell vaccines and others |
| 11:20 |
R. Strugnell
University of Melbourne, Australia |
Whither Salmonella vaccine, vectors |
| 11:45 |
C.B. Palatnik de Sousa
Federal University of Rio de Janeiro, Brazil |
Vaccines for Leishmaniasis in the forecoming 25 years |
| 12:00 |
A.Zanetti
University of Milan, Italy |
Vaccination against Hepatitis B: A historical overview |
| 12:15 |
A.Bianchi
University at Buffalo, USA |
The role of the CYS-PAM3 motif of Nontypeable Haemophilus Influenzae OMP P6 in stimulating innate immune responses |
| 12:30 |
K.Roland
AVANT Immunotherapeutics, Inc., USA |
Construction and preclinical evaluation of a V. cholerae Peru-15 (CholeraGarde®) strain that expresses high levels of CTB for use as a vaccine against enterotoxigenic Escherichia coli |
| 12:45 |
F. Roohvand
Pasteur Institute of Iran, Iran |
Construction and evaluation of CD8-polytope DNA constructs based on immunodominant and sub-dominant HCV epitopes |
| 13:00 |
M. Doskaya
Ege University Medical School, Turkey |
Immunogenic anti-0sporozooite vaccine candidate against Toxoplasmosis |
| 13:10 |
Lunch, poster session 1 and exhibition viewing |
|
Session 5
Immunological aspects of vaccines; Adjuvanting vaccines – methods, targets, mechanisms, materials and presentation |
| 14:15 |
I.G. Ovsyannikova
Mayo Clinic College of Medicine, USA |
Influence of host genetic variation on the immune response to the smallpox vaccine |
| 14:22 |
J. Kyd
Central Queensland University, Australia |
Targeting mucosal vaccine delivery and differential immune modulation against respiratory bacterial infection |
| 14:37 |
V.E.J.C. Schijns
Intervet Int. BV, Netherlands |
The importance and mechanistic activities of vaccine adjuvants |
| 14:52 |
W.A. Jeffries
University of British Columbia, Canada |
TAP as a general adjuvant to augment immune responses to low-dose vaccination |
| 15:07 |
K.S.Korsholm
Statens Serum Institut, Denmark |
The new versatile DDA-TDB adjuvant system enhances the protective efficacy of vaccines against both malaria and tuberculosis |
| 15:22 |
B.D. Livingston
Dynavax Technologies, USA |
Development of immunostimulatory Oligonucleotides as vaccine adjuvants |
| 15:29 |
Ch. Hartoonian
Tehran University of Medical Sciences, Iran |
Administration of GM-CSF (Granulocyte-Monocyte Colony Stimulating Factor) and IL-23 enhances immune responses generated against Hepatitis C virus core DNA prime-protein boost immunization |
| 15:36 |
X.M. Song
Zhejiang University, China |
Adjuvant activity of Ginseng nanoparticles (Ginsomes) on the immune responses to Ovalbumin in BABG/c mice |
| 15:45 |
Refreshments, poster session 2 and exhibition viewing |
|
Session 6
Correlates of protection; clinical trials; regulatory agencies |
| 16:15 |
S.A. Plotkin
University of Pennsylvania, USA, Sanofi Pasteur, USA |
Correlates of vaccine induced immunity |
| 16:45 |
K. Gijzen
Netherlands Vaccine Institute (NVI), Netherlands |
Identification of new correlates of protection against influenza |
| 17:00 |
J.A.C. Schalk
Centre for biological Medicines and Medical Technology, Netherlands |
Infectivity PCR, a rapid method for detection and quantification of infectious viruses in live virus vaccines and gene therapeutics |
| 17:15 |
K.A.Bryant
University of Louisville, USA |
Safety and immunogenicity of a 13-valent Pneumococcal conjugate vaccine in infants |
| 17:30 |
C. Martin
University of Zaragoza, Spain |
Attenuated live vaccines against tuberculosis based in phoP inactivation: Further studies on safety, one step to clinical trials |
| 17:45 |
A.Vila-Corcoles
Institut Catala de la Salut, Spain |
Clinical effectiveness of pneumococcal vaccination in order adults with chronic respiratory disease |
| 18:00 |
Discussion |
|
| 19:00 |
Congress dinner with after-dinner speech, “Vaccine”: The journal and the future; R.E. Spier, University of Surrey, UK and Editor of Vaccine |
|
| Tuesday December 11, 2007 |
Session 7
Vaccines to non-infectious diseases; Cancer vaccines; Therapeutic vaccinations; Social vaccines; Vaccines to addiction |
| 8:30 |
R.G. van der Most
National Research Centre for Asbestos Related Diseases, Australia |
Turning the tumor into its own vaccine: Adding context to content |
| 8:45 |
E. Barr
Merck Research Laboratories, USA |
Primary prevention of cervical cancer and beyond – GARDASIL (Quadrivalent Human Papillomavirus {HPV] Vaccine) |
| 9:00 |
T.G. Wu
University of Minnesota, USA |
A potential roadmap for the development of cancer vaccines |
| 9:15 |
L. Krishnan
National Research Council-Institute for Biological Sciences, Canada |
Archaeosome adjuvants for tumor immunotherapy: Modulation of potent CD8+ T Cell memory of the central and effector phenotype, comparison to live bacterial vaccine vectors |
| 9:22 |
H. Hossein
Velindre NHS Trust, UK |
Evaluation of clinical-grade poly I:C-analogue (Ampligen®) as a potential adjuvant for human dendritic cell (DC) maturation for cell mediated cancer immunotherapy |
| 9:29 |
J. Jasinska
Medical University of Vienna, Austria |
Virosome-based multi-epitope vaccine against Her-2/neu overexpressing tumors: from bench to clinic |
| 9:35 |
R.W. Hepler
Merck Research Laboratories, USA |
Development of multi antigenic peptide antigens as the basis for a novel vaccine approach to Alzheimer’s disease |
| 9:50 |
A.Neisig
Pharmexa A/S, Denmark |
Development of a PADRE-RANKL vaccine against osteoporosis |
| 10:05 |
B. Anton
National Institute of Psychiatry, Mexico |
Preclinical studies on generation of highly immunogenic conjugates for psychothropic substances |
| 10:20 |
J.A. Duckworth
National Research Centre for Possum Biocontrol at Landcare Research, New Zealand |
Fertility control vaccines for wildlife management in New Zealand |
| 10:35 |
Discussion |
|
| 10:45 |
Refreshments, poster session 2 and exhibition viewing |
|
Session 8
Modern vaccine designs; T-Cells, genomics, immunogenetics; Conjugates; Cross-fertilization between human and veterinary areas |
| 11:15 |
P.L. Nara
Biological Mimetics, Inc., USA |
Circumventing deceptive imprinting: A maginot line to making broadly protective vaccines? |
| 11:45 |
R. Rappuoli
Novartis Vaccines, Italy |
Vaccines in the era of genomics and toll-like receptors |
| 12:15 |
.Jordan
ProBioGen AG, Germany |
The duck Cell Line AGE1cr for the production of vaccine vectors |
| 12:27 |
S.C. Wu
National Tsing Hua University, Taiwan |
High genetic stability of dengue virus propagation in MRC-5 cells and the comparison of viral yields to Vero cells on microcarriers |
| 12:39 |
Discussion |
|
| 12:45 |
Lunch, poster session 2 and exhibition viewing |
|
Session 9
Vaccine formulation, preservations, storage, delivery; Attitudes to vaccination |
| 13:45 |
B. Weniger
U.S. Centers for Disease Control and Prevention (CDC), USA |
Alternative and future vaccine delivery technologies and preparedness for mass campaigns |
| 14:15 |
H. Kiyona
University of Tokyo and CREST, Japan |
The mucosal immune system for the development of needle-a and cold chain-free vaccine |
| 14:30 |
P-P. Pastoret
World Organisation for Animal Health ,France |
The story of fox vaccination against rabies using a recombinant Vaccinia-rabies virus |
| 14:45 |
D.R.M. Negri
Istituto Superiore di Sanita, Italy |
Successful immunization with a single injection of nonintegrating lentiviral vector |
| 15:00 |
R. Greco
University of Milan, Italy |
Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine |
| 15:15 |
A.Luxembourg
Ichor, USA |
Electroporation based delivery improvise immunogenicity and potency of DNA vaccines |
| 15:30 |
J.F. McGrath
Central Queensland University, Australia |
Evaluation of bacterial ghost mucosal delivery technology on immunogenicity of nontypeable Haemophilus influenzae mono- and multi-valent antigens |
| 15:37 |
J.H.B.H. Hirschberg
Netherlands Vaccine Institute, Netherlands |
BioneedlesTM: A parenteral vaccine technology platform avoiding classical syringe and needle |
| 15:44 |
B.H.A. Kremer
OctoPlus NV, Netherlands |
Single-shot vaccines: controlled delivery by OctoVAX-TM microspheres |
| 15:51 |
Discussion |
|
| 16:00 |
Refreshments, poster session 2 and exhibition viewing |
|
Session 10
Social issues with vaccines and vaccination
Part two: Where are we going locally and globally and how we are going to pay for it |
| 16:30 |
A.McDermott
International AIDS Vaccine Initiative, USA |
Fostering innovation in AIDS vaccine development |
| 17:00 |
J.B. Campbell
University of Toronto, Canada |
Vaccination attitudes of medical, chiropractic and naturopathic students |
| 17:30 |
W.L. Straus
Merck & Co., Inc., USA |
Ethical considerations in international vaccine research: Consensus and evolving debate |
| 17:45 |
S. Hilton
MRC, Social and Public Health Sciences Unite, UK |
Aligning advice with the evidence: Trends in commentaries and editorials during the MMR controversy |
| 18:00 |
G. Gandhi
International AIDS Vaccine Initiative, USA |
Demand forecasting for global health products: Recent advances and the role of Public-Private Partnerships (PDPs) (PANEL SESSION) |
|
| Concluding lecture: “The end of the beginning” … Vaccine for the next 25 years, J. Oxford, St Bartholomew’s and the Royal London Hospital, Queen Mary’s School of Medicine and Dentistry and Retroscreen Virology Ltd., UK |
|
|
|
